Edgewise Therapeutics Inc
NASDAQ:EWTX
Edgewise Therapeutics Inc
NASDAQ:EWTX
Price:
29.66
USD
-1.53%
Market Closed
Market Cap:
$3.1B
Income Statement
Earnings Waterfall
Edgewise Therapeutics Inc
Edgewise Therapeutics Inc
Income Statement
Edgewise Therapeutics Inc
Edgewise Therapeutics Inc
Currency: USD
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(17)
|
(21)
|
(27)
|
(37)
|
(43)
|
(51)
|
(57)
|
(62)
|
(72)
|
(83)
|
(91)
|
(103)
|
(114)
|
(123)
|
(136)
|
(147)
|
(159)
|
(170)
|
(175)
|
(181)
|
|
| Selling, General & Administrative |
(2)
|
(3)
|
(6)
|
(9)
|
(11)
|
(13)
|
(15)
|
(16)
|
(18)
|
(20)
|
(21)
|
(23)
|
(23)
|
(25)
|
(26)
|
(29)
|
(32)
|
(34)
|
(36)
|
(37)
|
|
| Research & Development |
(15)
|
(17)
|
(22)
|
(28)
|
(32)
|
(38)
|
(42)
|
(47)
|
(54)
|
(63)
|
(70)
|
(80)
|
(91)
|
(99)
|
(110)
|
(118)
|
(127)
|
(136)
|
(139)
|
(144)
|
|
| Operating Income |
(17)
N/A
|
(21)
-21%
|
(27)
-31%
|
(37)
-35%
|
(43)
-18%
|
(51)
-18%
|
(57)
-12%
|
(62)
-9%
|
(72)
-15%
|
(83)
-15%
|
(91)
-11%
|
(103)
-12%
|
(114)
-11%
|
(123)
-8%
|
(136)
-10%
|
(147)
-8%
|
(159)
-8%
|
(170)
-7%
|
(175)
-3%
|
(181)
-4%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
4
|
7
|
10
|
13
|
14
|
18
|
20
|
23
|
25
|
24
|
24
|
24
|
|
| Pre-Tax Income |
(17)
N/A
|
(21)
-21%
|
(27)
-31%
|
(36)
-34%
|
(43)
-17%
|
(51)
-18%
|
(56)
-11%
|
(61)
-8%
|
(68)
-11%
|
(76)
-12%
|
(81)
-7%
|
(89)
-10%
|
(100)
-12%
|
(106)
-6%
|
(116)
-9%
|
(124)
-7%
|
(134)
-8%
|
(146)
-9%
|
(151)
-3%
|
(157)
-4%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(17)
|
(21)
|
(27)
|
(36)
|
(43)
|
(51)
|
(56)
|
(61)
|
(68)
|
(76)
|
(81)
|
(89)
|
(100)
|
(106)
|
(116)
|
(124)
|
(134)
|
(146)
|
(151)
|
(157)
|
|
| Net Income (Common) |
(17)
N/A
|
(21)
-21%
|
(27)
-31%
|
(36)
-34%
|
(43)
-17%
|
(51)
-18%
|
(56)
-11%
|
(61)
-8%
|
(68)
-11%
|
(76)
-12%
|
(81)
-7%
|
(89)
-10%
|
(100)
-12%
|
(106)
-6%
|
(116)
-9%
|
(124)
-7%
|
(134)
-8%
|
(146)
-9%
|
(151)
-3%
|
(157)
-4%
|
|
| EPS (Diluted) |
-0.36
N/A
|
-0.43
-19%
|
-0.56
-30%
|
-0.74
-32%
|
-1.14
-54%
|
-1.03
+10%
|
-1.14
-11%
|
-1.17
-3%
|
-1.26
-8%
|
-1.19
+6%
|
-1.28
-8%
|
-1.42
-11%
|
-1.57
-11%
|
-1.2
+24%
|
-1.23
-3%
|
-1.32
-7%
|
-1.45
-10%
|
-1.55
-7%
|
-1.43
+8%
|
-1.49
-4%
|
|
Switch to:
Switch to:
See Also
Discover More
